Okyo Pharma Share Discussion Threads

[spurs90] 24/7/2020 05:18

IQ-AI Ltd

("IQ-AI" or the "Company")



Study Using Imaging Biometrics' Brain Tumor Image Analysis Software Wins 2019's Top Award from the American Journal of Neuroradiology



Imaging Biometrics, LLC, (IB), a wholly-owned subsidiary of IQ-AI and a recognized industry leader in quantitative imaging analysis for brain tumor diagnosis and treatment, is proud to announce its software was featured in the top-award-winning article in the March 2020 issue of the American Journal of Neuroradiology (AJNR). AJNR, a publication of the American Society of Neuroradiology, presented the article with the Lucien Levy Award, recognizing it as the best original research paper accepted in 2019.



The article, "Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies" (hxxp://www.ajnr.org/content/early/2020/03/12/ajnr.A6486), showcases a study led by Dr. Leland Hu, MD (Mayo Clinic in Arizona) that demonstrates the superior ability of IB's vascular mapping software to identify and distinguish recurrent high-grade brain tumor from benign treatment effects. These treatment effects occur frequently in patients undergoing standard chemoradiation treatment after surgery, and typically resolve over a period of several months post-treatment. However, these tissues appear similar on standard MRI creating a major challenge for treating physicians. As described, IB's exclusive software, which provides a measurement of tumor burden within each image voxel, addresses this need.

IB's software also streamlines workflow by eliminating time-consuming manual processing steps, delivering the power of advanced research analysis in a clinical setting. Dr. Hu's study demonstrates that IB's image Standardization algorithm is key to making this possible. Further, the study shows that IB's vascular mapping is a reliable solution for MR images from multiple vendors.

"Our relative cerebral blood volume maps have the potential to aid clinical decision-making before surgery, during recovery, and during follow-up treatment," said Michael Schmainda, CEO of IB. "This study not only proves the clinical relevance of vascular mapping in tumors for monitoring treatment response, it also highlights the workflow benefits IB provides through automation. Our solutions are built on decades of specialized experience in brain tumor imaging, which allows us to create fully automated methods that are both repeatable and robust. This optimized workflow certainly has the potential of becoming the consensus methodology, as the paper cites," Schmainda added.

[spurs90] 24/7/2020 05:16

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[stg8123] 23/7/2020 12:48

Spurs do you realise this is okyo not iqai ?

[spurs90] 23/7/2020 11:44

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 11:39

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.


Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 11:38

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics in Collaboration With Three Top Imaging Centers

Awarded $2.57m NIH Grant





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) - National Cancer Institute (NCI). Funding for this effort begins 1st July with the primary purpose of optimising and validating multi-vendor quantitative perfusion tools for the prediction of brain tumor response to therapy on a patient-specific basis.

Principal Investigator, Chad Quarles, PhD, Professor and Chair of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will lead this multi-institutional effort to provide brain tumor physicians with a novel MRI method that provides several different measures of tumor biology using just one MRI technique, called SAGE (spin and gradient echo [MRI]). The additional biological information will help doctors determine how best to combine therapies, and will complement IB's current methods of monitoring treatment response. This NIH-funded effort also includes a plan to harmonise the way SAGE data is collected and analysed across sites and MRI vendors. IB's experience in providing vendor-neutral and standardised software is key to this effort, and IB's participation in this effort will further expand its footprint as the recognised leader in brain cancer imaging and assessing treatment response.


Michael Schmainda, CEO of IB, added, "Since our inception in 2007, NIH grant funding has helped fuel our business by enabling us to accelerate the development and translation of novel imaging technologies into practical products. Not only does this grant provide a financial boost for IB, it further strengthens our relationships with recognized leaders in MR imaging."

[spurs90] 23/7/2020 11:38

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.


Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:50

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics in Collaboration With Three Top Imaging Centers

Awarded $2.57m NIH Grant





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) - National Cancer Institute (NCI). Funding for this effort begins 1st July with the primary purpose of optimising and validating multi-vendor quantitative perfusion tools for the prediction of brain tumor response to therapy on a patient-specific basis.

Principal Investigator, Chad Quarles, PhD, Professor and Chair of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will lead this multi-institutional effort to provide brain tumor physicians with a novel MRI method that provides several different measures of tumor biology using just one MRI technique, called SAGE (spin and gradient echo [MRI]). The additional biological information will help doctors determine how best to combine therapies, and will complement IB's current methods of monitoring treatment response. This NIH-funded effort also includes a plan to harmonise the way SAGE data is collected and analysed across sites and MRI vendors. IB's experience in providing vendor-neutral and standardised software is key to this effort, and IB's participation in this effort will further expand its footprint as the recognised leader in brain cancer imaging and assessing treatment response.


Michael Schmainda, CEO of IB, added, "Since our inception in 2007, NIH grant funding has helped fuel our business by enabling us to accelerate the development and translation of novel imaging technologies into practical products. Not only does this grant provide a financial boost for IB, it further strengthens our relationships with recognized leaders in MR imaging."

[spurs90] 23/7/2020 07:49

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.


Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:45

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics in Collaboration With Three Top Imaging Centers

Awarded $2.57m NIH Grant





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) - National Cancer Institute (NCI). Funding for this effort begins 1st July with the primary purpose of optimising and validating multi-vendor quantitative perfusion tools for the prediction of brain tumor response to therapy on a patient-specific basis.

Principal Investigator, Chad Quarles, PhD, Professor and Chair of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will lead this multi-institutional effort to provide brain tumor physicians with a novel MRI method that provides several different measures of tumor biology using just one MRI technique, called SAGE (spin and gradient echo [MRI]). The additional biological information will help doctors determine how best to combine therapies, and will complement IB's current methods of monitoring treatment response. This NIH-funded effort also includes a plan to harmonise the way SAGE data is collected and analysed across sites and MRI vendors. IB's experience in providing vendor-neutral and standardised software is key to this effort, and IB's participation in this effort will further expand its footprint as the recognised leader in brain cancer imaging and assessing treatment response.


Michael Schmainda, CEO of IB, added, "Since our inception in 2007, NIH grant funding has helped fuel our business by enabling us to accelerate the development and translation of novel imaging technologies into practical products. Not only does this grant provide a financial boost for IB, it further strengthens our relationships with recognized leaders in MR imaging."

[spurs90] 23/7/2020 07:42

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.


Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:41

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.


This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.

Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.

Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 07:40

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics and Medical College of Wisconsin Awarded Grant



Imaging Biometrics™, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Medical College of Wisconsin ("MCW"), has received a $2.75 million, five-year grant award from the National Institutes of Health - National Cancer Institute. As a participant on this grant, IB will utilise the funding to assist in the translation of machine learned, scientifically validated algorithms to software solutions that provide new clinical insight on advanced brain tumor treatment and management.





David Smith, CEO of IB, commented, "Our grant and contract development work are important stimuli at Imaging Biometrics. This grant will provide income for the Company for the next 5 years, as well as, further catalyse the development of our quantitative imaging tools, enabling us to apply the result of this collaboration with MCW to our commercial products."

[spurs90] 23/7/2020 07:38

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.


This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.

Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.

Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

Trevor Brown CEO of IQ-AI Limited commented "In addition to this excellent news, I am please to report that the process of finding a buyer for Stonechecker software has now recommenced with discussions under way with two parties. There is no certainty of a satisfactory conclusion of these discussions and we will update shareholders as appropriate. The Board is also exploring a new initiative in telemedicine and looking at the wider application of IB technology and products."

[spurs90] 23/7/2020 07:36

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.


This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.

Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.

Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

Trevor Brown CEO of IQ-AI Limited commented "In addition to this excellent news, I am please to report that the process of finding a buyer for Stonechecker software has now recommenced with discussions under way with two parties. There is no certainty of a satisfactory conclusion of these discussions and we will update shareholders as appropriate. The Board is also exploring a new initiative in telemedicine and looking at the wider application of IB technology and products."

[spurs90] 23/7/2020 07:35

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.


Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:33

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.


This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.

Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.

Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 07:31

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics in Collaboration With Three Top Imaging Centers

Awarded $2.57m NIH Grant





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) - National Cancer Institute (NCI). Funding for this effort begins 1st July with the primary purpose of optimising and validating multi-vendor quantitative perfusion tools for the prediction of brain tumor response to therapy on a patient-specific basis.

Principal Investigator, Chad Quarles, PhD, Professor and Chair of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will lead this multi-institutional effort to provide brain tumor physicians with a novel MRI method that provides several different measures of tumor biology using just one MRI technique, called SAGE (spin and gradient echo [MRI]). The additional biological information will help doctors determine how best to combine therapies, and will complement IB's current methods of monitoring treatment response. This NIH-funded effort also includes a plan to harmonise the way SAGE data is collected and analysed across sites and MRI vendors. IB's experience in providing vendor-neutral and standardised software is key to this effort, and IB's participation in this effort will further expand its footprint as the recognised leader in brain cancer imaging and assessing treatment response.


Michael Schmainda, CEO of IB, added, "Since our inception in 2007, NIH grant funding has helped fuel our business by enabling us to accelerate the development and translation of novel imaging technologies into practical products. Not only does this grant provide a financial boost for IB, it further strengthens our relationships with recognized leaders in MR imaging.

[spurs90] 23/7/2020 07:27

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.



Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.



Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

[spurs90] 23/7/2020 07:26

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 07:24

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".

[spurs90] 23/7/2020 07:23

IQ-AI Ltd

("IQ-AI" or the "Company"



IB Neuro, the Recognised National Standard in MRI DSC





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognised leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announced that the MRI DSC perfusion technology, first made commercially available in IB Neuro™, earned recognition as the national standard for use in high-grade brain tumors. This recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The Committee's findings, published in Neuro Oncology (Consensus Recommendations for a DSC MRI Protocol), provide evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective. DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumors.



This national consensus is long overdue. Despite its widespread use, MRI-DSC imaging has been plagued by inconsistent and suboptimal ways of acquiring and processing DSC-MRI data resulting in mixed opinions regarding its usefulness. Instead, IB Neuro has been honed and developed, over two decades, to account for subtle nuances in data acquisition and post-processing. It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.



Standardising on the most common perfusion MRI technology is good news for patients and their care providers. Per the National Brain Tumor Soceity, in the US alone there are over 700,000 people living with a primary brain tumor and another 87,000 will be diagnosed in 2020. Each year these patients will have 4-6 MRI scans. These patients represent the highest initial cost of care for any cancer group, with an annualised average cost of care approaching $150,000 per patient. Standardising on a recommended best imaging practice may help impact these costs.



Michael Schmainda, CEO of IB, added, "We continue to advance our understanding and application in MRI-DSC imaging, and IB Neuro is foundational in that regard. The automated and quantitative processing in IB Neuro is also the default standard for the National Clinical Trials Network and is widely available for routine clinical use".



Trevor Brown CEO of IQ-AI Limited commented "In addition to this excellent news, I am please to report that the process of finding a buyer for Stonechecker software has now recommenced with discussions under way with two parties. There is no certainty of a satisfactory conclusion of these discussions and we will update shareholders as appropriate. The Board is also exploring a new initiative in telemedicine and looking at the wider application of IB technology and products."

[spurs90] 23/7/2020 07:20

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration



On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.



IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging.



By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.



Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.



Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.



IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

[spurs90] 23/7/2020 07:19

IQ-AI Ltd

("IQ-AI" or the "Company")



Study Using Imaging Biometrics' Brain Tumor Image Analysis Software Wins 2019's Top Award from the American Journal of Neuroradiology



Imaging Biometrics, LLC, (IB), a wholly-owned subsidiary of IQ-AI and a recognized industry leader in quantitative imaging analysis for brain tumor diagnosis and treatment, is proud to announce its software was featured in the top-award-winning article in the March 2020 issue of the American Journal of Neuroradiology (AJNR). AJNR, a publication of the American Society of Neuroradiology, presented the article with the Lucien Levy Award, recognizing it as the best original research paper accepted in 2019.



The article, "Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies" (hxxp://www.ajnr.org/content/early/2020/03/12/ajnr.A6486), showcases a study led by Dr. Leland Hu, MD (Mayo Clinic in Arizona) that demonstrates the superior ability of IB's vascular mapping software to identify and distinguish recurrent high-grade brain tumor from benign treatment effects. These treatment effects occur frequently in patients undergoing standard chemoradiation treatment after surgery, and typically resolve over a period of several months post-treatment. However, these tissues appear similar on standard MRI creating a major challenge for treating physicians. As described, IB's exclusive software, which provides a measurement of tumor burden within each image voxel, addresses this need.

IB's software also streamlines workflow by eliminating time-consuming manual processing steps, delivering the power of advanced research analysis in a clinical setting. Dr. Hu's study demonstrates that IB's image Standardization algorithm is key to making this possible. Further, the study shows that IB's vascular mapping is a reliable solution for MR images from multiple vendors.

"Our relative cerebral blood volume maps have the potential to aid clinical decision-making before surgery, during recovery, and during follow-up treatment," said Michael Schmainda, CEO of IB. "This study not only proves the clinical relevance of vascular mapping in tumors for monitoring treatment response, it also highlights the workflow benefits IB provides through automation. Our solutions are built on decades of specialized experience in brain tumor imaging, which allows us to create fully automated methods that are both repeatable and robust. This optimized workflow certainly has the potential of becoming the consensus methodology, as the paper cites," Schmainda added.